Trials / No Longer Available
No Longer AvailableNCT03810287
The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To prescribe oral domperidone for patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy.
Detailed description
The primary objective of this study is to prescribe oral domperidone for patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Domperidone | Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose. |
Timeline
- First posted
- 2019-01-18
- Last updated
- 2025-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03810287. Inclusion in this directory is not an endorsement.